Geode Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Geode Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-113,002	Closed	-$60K	–	4278
2019 Q4	$60K	Sell	113,002 -31,761	-22%	-$77K	﹤0.01%	4065
2019 Q3	$551K	Sell	144,763 -1,886	-1%	-$6.79K	﹤0.01%	3444
2019 Q2	$975K	Buy	146,649 +23,267	+19%	+$88.6K	﹤0.01%	3246
2019 Q1	$438K	Buy	123,382 +39,631	+47%	+$215K	﹤0.01%	3484
2018 Q4	$331K	Buy	83,751 +2,668	+3%	+$34.1K	﹤0.01%	3519
2018 Q3	$1.6M	Buy	81,083 +11,253	+16%	+$284K	﹤0.01%	3005
2018 Q2	$2.22M	Buy	69,830 +41,865	+150%	+$1.51M	﹤0.01%	2797
2018 Q1	$1.03M	Buy	27,965 +11,853	+74%	+$779K	﹤0.01%	3104
2017 Q4	$1.27M	Buy	+16,112	New	+$1.19M	﹤0.01%	3004

Geode Capital Management's MLNT Position: Q1 2020 in Review

Geode Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 113,002 shares — an estimated $60K sold.

Geode Capital Management first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $2.22M in Q2 2018. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Geode Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Geode Capital Management sold 113,002 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $60K.
Geode Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
Geode Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $2.22M in Q2 2018.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Geode Capital Management's 13F filing for Q1 2020, filed 14 May 2020.